论文部分内容阅读
发展新的抗麻风药物是麻风治疗研究的重要内容之一,首要目的是发现更强有力的杀菌药。我们应用鼠麻风菌感染模型观察17种利福霉素衍生物的治疗效果并与利福平(简称RFP)作比较,发现异丁基哌嗪力复霉素(简称R-76-1)明显超过RFP,即使R-76-1的剂量减少到RFP的1/3,仍然取得稍优于RFP的疗效。为此,我们进一步观察R-76-1对麻风的实验治疗效果,并与RFP作比较。已知RFP在麻风菌鼠足垫感染模型显示很强的杀菌作用,一定剂量下用常规动力法给药(足垫接种麻风菌后70天到140天给药),
The development of new anti-leprosy drugs is an important part of leprosy research. The primary objective is to find stronger bactericidal drugs. We observed the therapeutic effects of 17 rifamycin derivatives using a model of leprosy infection and compared it to rifampicin (RFP) and found that isobutylpiperazine rifamycin (R-76-1) was significantly Exceed the RFP, even if the dose of R-76-1 reduced to 1/3 of RFP, still achieved slightly better than RFP curative effect. To this end, we further observed the experimental treatment effect of R-76-1 on leprosy and compared it with RFP. RFP is known to have a strong bactericidal effect in models of footpad infection in leprosy mice and is administered by conventional dynamic methods at certain doses (administration of leprosy 70 to 140 days after footpad inoculation)